Jana Konstantinovna Mangasarova

Evaluation of the effectiveness of hematopoietic blood stem cell mobilization using empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases: the experience of several centers in the Russian Federation. A retrospective study

Ekaterina Nesterova, Jana Konstantinovna Mangasarova, Madina Bagova, Е. А. Фастова et autres

Aim. To evaluate the effectiveness of autologous hematopoietic stem cell (HSC) mobilization with empegfilgrastim in patients with lymphoproliferative diseases (LPDs) and to identify prognostic factors affecting the effectiveness of mobilization. Materials and methods. The paper analyzes the effectiveness of HSC mobilization with …

id, ru, pk (code pays fourni par la source)

CNS involvement and the feasibility of intratecal chemotherapy administration in patients with a nodal form of diffuse large B-cell lymphoma not otherwise specified. Data of prospective study

Aminat Umaraskhabovna Magomedova, Anna Misyurina, Jana Konstantinovna Mangasarova, Liliya Gamilevna Gorenkova et autres

Aim of the issue was to determine indications for intratecal chemotherapy drugs administration to prevent relapse of diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) involvement. MATERIALS AND METHODS: Since January 2009 to December 2018 102 patients with primary nodal …

Myc+ Single-Hit Lymphoma Patients had Benefit from Dose-Intensified Chemotherapy

Anna Misyurina, Elena Alexandrovna Baryakh, Sergey Kravchenko, Alla Mikhailovna Kovrigina et autres

ru (code pays fourni par la source)

Chemotherapy of Primary Mediastinal B-Cell Lymphoma

Jana Konstantinovna Mangasarova, Aminat Umaraskhabovna Magomedova, Ekaterina Nesterova, Hunan L. Julhakyan et autres

ru (code pays fourni par la source)

Leukemization of Follicular Lymphoma: Diagnostic Features and Clinical Course of a Rare Form of the Disease

Ekaterina Nesterova, Alla Mikhailovna Kovrigina, Jana Konstantinovna Mangasarova, Lybov Plastinina et autres

ru (code pays fourni par la source)

The High Efficiency of AutoSCT in the Treatment of Refractory Follicular Lymphoma (FL): Results of the First Russian Prospective Study

Ekaterina Nesterova, Sergey Kravchenko, Jana Konstantinovna Mangasarova, Vladimir I. Vorobyev et autres

ru (code pays fourni par la source)

Pregnancy and Primary Mediastinal B-Cell Lymphoma

Jana Konstantinovna Mangasarova, Sergey Kravchenko, Aminat Umaraskhabovna Magomedova, Elena Alexandrovna Baryakh et autres

Abstract Introduction. Favorable therapeutic regimen for pregnant women with primary mediastinal B-cell Lymphoma (PMBCL) is determined by tumor mass, somatic status, period of pregnancy and potential risk of teratogenic effects of medications which penetrate through placenta. Aim. To estimate chemotherapy efficacy of …

ru (code pays fourni par la source)

Intensive Chemotherapy of 107 Primary Mediastinal B-Cell Lymphoma Patients. Single Center Experience

Jana Konstantinovna Mangasarova, Sergey Kravchenko, Aminat Umaraskhabovna Magomedova, Anna Misyurina et autres

Abstract Introduction. Primary mediastinal B-cell lymphoma (PMBCL) amounts from 0,9 to 4% of Non-Hodgkin Lymphomas. Predominantly suffer young women. All relapses in PMBCL occur as early events. Taking into account unfavorable prognosis in case of relapse or progression of PMBCL (2-year overall …

ru (code pays fourni par la source)

Less Toxic Gemcitabine-Oxaliplatin Based Induction Regimen (R-GIDIOX) Prior to Autologous SCT Produces Outcomes Similar to High-Dose Cytarabine Containing Intensive Induction Regimen in Mantle Cell Lymphoma – a Follow up Report of the Multicenter Study

Vladimir I. Vorobyev, Sergei K. Kravchenko, Э Г Гемджян, Jana Konstantinovna Mangasarova et autres

Abstract Background: MCL is B-cell neoplasm diagnosed predominantly among older men. (R)CHOP-like regimens demonstrated high response rate, but the event-free survival (EFS) and overall survival (OS) are disappointingly short - 16-20 months and 3-4 years, respectively. An addition of high-dose AraC (12 …

ru (code pays fourni par la source)

B-Cell Lymphoma Unclassified, Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma: A Single Center Experience of Intensive Chemotherapy with and without Auto-SCT

Anna E. Lukina, Elena Alexandrovna Baryakh, Alla Mikhailovna Kovrigina, Э Г Гемджян et autres

Abstract Background: According to current data B-cell lymphoma unclassified (BCLU), intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma represents a highly aggressive type of lymphoma with dramatically bad response for chemotherapy. Cases with translocation of two genes (MYC and BCL2 or …

ru (code pays fourni par la source)

Intensive Induction, Autologous Stem Cell Transplantation and Rituximab Maintenance Has Changed Event Free Survival and Overall Survival in Mantle Cell Lymphoma Patients. Using Gemcitabine and Oxaliplatin in First Line Therapy

Vladimir I. Vorobyev, Yuri Yu. Lorie, Е Е Звонков, Eduard G. Gemdjian et autres

Abstract Abstract 2034 Background: Mantle cell lymphoma (MCL) is aggressive B-cell neoplasm diagnosed predominantly among elderly men. (R)CHOP-like schemes are effective in remission induction, but the progression-free survival is disappointingly short (median 16–20 months) with median overall survival of 3–4 years. Upfront …

ru, qa (code pays fourni par la source)

Molecular Signature Distinguishes Between Primary Mediastinal B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma with Primary Involvment of Mediastinal Lymph Nodes

Jana Konstantinovna Mangasarova, Andrew V Misuyrin, Aminat Umaraskhabovna Magomedova, Sergey Kravchenko

Abstract Abstract 2654 Background. Primary mediastinal (thymic) B-cell lymphoma (PMBL) has been recognized as a subtype of diffuse large B-cell lymphoma (DLBCL). It has its distinctive clinical and morphological features but differs from other types of DLBCL due to peculiar immunophenotype and …

ru (code pays fourni par la source)